PHAXIAM Therapeutics S.A. 0QSS.L Stock
PHAXIAM Therapeutics S.A. Price Chart
PHAXIAM Therapeutics S.A. 0QSS.L Financial and Trading Overview
| PHAXIAM Therapeutics S.A. stock price | 2.87 EUR |
| Previous Close | 0.94 EUR |
| Open | 0 EUR |
| Bid | 0 EUR x 0 |
| Ask | 0 EUR x 0 |
| Day's Range | 0 - 0 EUR |
| 52 Week Range | 0 - 1.29 EUR |
| Volume | 15.2K EUR |
| Avg. Volume | 15.12K EUR |
| Market Cap | 146.11K EUR |
| Beta (5Y Monthly) | 2.129118 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.733 EUR |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
0QSS.L Valuation Measures
| Enterprise Value | 4M EUR |
| Trailing P/E | N/A |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 0.021981495 |
| Price/Book (mrq) | 1.2443856 |
| Enterprise Value/Revenue | 0.601 |
| Enterprise Value/EBITDA | -0.16 |
Trading Information
PHAXIAM Therapeutics S.A. Stock Price History
| Beta (5Y Monthly) | 2.129118 |
| 52-Week Change | -15.83% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 1.29 EUR |
| 52 Week Low | 0 EUR |
| 50-Day Moving Average | 0.89 EUR |
| 200-Day Moving Average | 0.82 EUR |
0QSS.L Share Statistics
| Avg. Volume (3 month) | 15.12K EUR |
| Avg. Daily Volume (10-Days) | 21.11K EUR |
| Shares Outstanding | 17.94M |
| Float | 27.99M |
| Short Ratio | N/A |
| % Held by Insiders | 6.59% |
| % Held by Institutions | 11.00% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | N/A |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | December 31, 2022 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | -3.42% |
| Operating Margin (ttm) | -408.41% |
| Gross Margin | 100.00% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -30.14% |
| Return on Equity (ttm) | -0.98% |
Income Statement
| Revenue (ttm) | 6.65M EUR |
| Revenue Per Share (ttm) | 0.21 EUR |
| Quarterly Revenue Growth (yoy) | 571.50% |
| Gross Profit (ttm) | N/A |
| EBITDA | -24972000 EUR |
| Net Income Avi to Common (ttm) | -228000 EUR |
| Diluted EPS (ttm) | -1.733 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 38.79M EUR |
| Total Cash Per Share (mrq) | 1.25 EUR |
| Total Debt (mrq) | 13.57M EUR |
| Total Debt/Equity (mrq) | 57.76 EUR |
| Current Ratio (mrq) | 3.651 |
| Book Value Per Share (mrq) | 0.757 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -31764000 EUR |
| Levered Free Cash Flow (ttm) | -21078250 EUR |
Profile of PHAXIAM Therapeutics S.A.
| Country | United Kingdom |
| State | N/A |
| City | Lyon |
| Address | 60 Avenue Rockefeller |
| ZIP | 69008 |
| Phone | 33 4 78 74 44 38 |
| Website | https://www.erytech.com |
| Industry | |
| Sector(s) | |
| Full Time Employees | 49 |
ERYTECH Pharma S.A., a biopharmaceutical company, focus on development of red blood cell-based therapeutics for cancer and orphan diseases in France and the United States. It develops eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing erymethionase, a preclinical product candidate that consists of methionine-?-lyase in red blood cells to target the amino acid metabolism of cancer cells and induce tumor starvation. ERYTECH Pharma S.A. was incorporated in 2004 and is headquartered in Lyon, France.
Q&A For PHAXIAM Therapeutics S.A. Stock
What is a current 0QSS.L stock price?
PHAXIAM Therapeutics S.A. 0QSS.L stock price today per share is 2.87 EUR.
How to purchase PHAXIAM Therapeutics S.A. stock?
You can buy 0QSS.L shares on the LSE exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for PHAXIAM Therapeutics S.A.?
The stock symbol or ticker of PHAXIAM Therapeutics S.A. is 0QSS.L.
How many shares does PHAXIAM Therapeutics S.A. have in circulation?
The max supply of PHAXIAM Therapeutics S.A. shares is 155.11K.
What is PHAXIAM Therapeutics S.A. Price to Earnings Ratio (PE Ratio)?
PHAXIAM Therapeutics S.A. PE Ratio is now.
What was PHAXIAM Therapeutics S.A. earnings per share over the trailing 12 months (TTM)?
PHAXIAM Therapeutics S.A. EPS is -1.733 EUR over the trailing 12 months.